Affiliations 

  • 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
  • 2 Department of Anatomical and cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China
  • 3 School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China
  • 4 Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR, China
  • 5 State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China
  • 6 Department of Otorhinolaryngology, Head and Neck Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
  • 7 Warwick Medical School, University of Warwick, Coventry, UK
  • 8 Department of Oral & Craniofacial Sciences and Oral Cancer Research and Coordinating Centre, University of Malaya, Kuala Lumpur, Malaysia
  • 9 School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • 10 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. trevor.pugh@utoronto.ca
  • 11 Department of Anatomical and cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China. kwlo@cuhk.edu.hk
Nat Commun, 2021 07 07;12(1):4193.
PMID: 34234122 DOI: 10.1038/s41467-021-24348-6

Abstract

Interplay between EBV infection and acquired genetic alterations during nasopharyngeal carcinoma (NPC) development remains vague. Here we report a comprehensive genomic analysis of 70 NPCs, combining whole-genome sequencing (WGS) of microdissected tumor cells with EBV oncogene expression to reveal multiple aspects of cellular-viral co-operation in tumorigenesis. Genomic aberrations along with EBV-encoded LMP1 expression underpin constitutive NF-κB activation in 90% of NPCs. A similar spectrum of somatic aberrations and viral gene expression undermine innate immunity in 79% of cases and adaptive immunity in 47% of cases; mechanisms by which NPC may evade immune surveillance despite its pro-inflammatory phenotype. Additionally, genomic changes impairing TGFBR2 promote oncogenesis and stabilize EBV infection in tumor cells. Fine-mapping of CDKN2A/CDKN2B deletion breakpoints reveals homozygous MTAP deletions in 32-34% of NPCs that confer marked sensitivity to MAT2A inhibition. Our work concludes that NPC is a homogeneously NF-κB-driven and immune-protected, yet potentially druggable, cancer.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.